You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
平安好醫生(01833.HK)擬增發總籌約78.56億港元 進一步發展集團核心業務
格隆匯 09-30 08:34

格隆匯9月30日丨平安好醫生(01833.HK)發佈公告,2020年9月30日(交易時段前),公司與配售代理訂立配售協議,內容有關根據配售協議所載條款及條件按配售價每股配售股份98.20港元配售合共8000萬股新股份,配售股份將根據一般授權配發及發行。

公司已委任瑞銀、摩根及平證證券為配售代理。配售股份相當於該公告日期已發行股份總數約7.5%及經配發及發行配售股份擴大後的已發行股份總數約7.0%。假設所有配售股份均根據配售事項發行,配售事項的所得款項總額預期約為78.56億港元,而配售事項的所得款項淨額預期約為78.24億港元,相當於每股配售股份的淨髮行價約為97.80港元。

配售所得款項淨額將用於進一步發展集團的核心業務,包括但不限於進一步擴充自建醫療團隊,增加科技研發投入,豐富會員產品種類,拓寬銷售渠道網路,以及潛在戰略投資,從而進一步夯實集團的競爭力。

公告表示,新冠疫情極大推動了互聯網醫療行業的發展,在中國,對線上診療服務的接受度大幅提高,互聯網醫療平台也在疫情期間發揮了重要的作用。在中國政府積極的政策支持下,互聯網醫療行業正步入高速增長的全新階段。

作為中國互聯網醫療領軍平台,公司計劃聚焦戰略升級並不斷加強自身服務能力和技術實力,包括但不限於:全面拓展用户渠道、整合線上線下醫療服務網路、擴張自建醫療團隊以及擴充第三方合作醫生網絡、圍繞以AI為基礎的領先科技構建核心壁壘,打造長期綜合競爭優勢。

此外,集團於截至2018年及2019年12月31日止年度的收入分別為人民幣33.38億元及人民幣50.65億元。配售事項的所得款項淨額將為公司進一步夯實在行業中的領先地位,為業務的拓展提供堅實的基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account